{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T21:16:46Z","timestamp":1776547006145,"version":"3.51.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T00:00:00Z","timestamp":1528675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T00:00:00Z","timestamp":1528675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Familial hypercholesterolemia (FH) is one of the most common causes of premature myocardial infarction (MI). However, The patterns of FH remained unrecognized in clinical care, especially in very young patients (VYPs, \u226435 years) with MI. The present study enrolled a total of 1,093 VYPs (\u226435 years) presenting a first MI. Clinical diagnosis of FH was made using Dutch Lipid Clinic Network criteria. Coronary severity was assessed by Gensini score (GS). Patients were followed for a median of 40-months with cardiac death, stroke, MI, post-discharge revascularization or unstable angina as primary endpoints. The detected rates of definite\/probable FH were 6.5%. The prevalence reached up to 10.3% in patients \u226425 years. The FH had similar levels of comorbidities but was younger, more likely to be very high risk (VHR) and had higher GS (p\u2009&lt;\u20090.05) than unlikely FH. Notably, the FH on prior lipid-lowering medication presented a lower GS compared to those untreated. Differences in event rates were similar in FH as unlikely FH (11.8% vs. 8.1%, adjusted hazard ratio 1.35 [0.64\u20132.86], p\u2009=\u20090.434) but patients on treatment improved outcome (6.5% vs. 10.5%, adjusted hazard ratio 0.35[0.13\u20130.95], p\u2009=\u20090.039). The early identification and treatment might be critical to reduce cardiovascular risk in VYPs with MI.<\/jats:p>","DOI":"10.1038\/s41598-018-27248-w","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T11:35:58Z","timestamp":1528198558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Familial hypercholesterolemia in very young myocardial infarction"],"prefix":"10.1038","volume":"8","author":[{"given":"Sha","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na-Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Gang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong-Yi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Qing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-Jue","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,11]]},"reference":[{"key":"27248_CR1","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.1161\/CIRCULATIONAHA.115.020701","volume":"133","author":"A Onorato","year":"2016","unstructured":"Onorato, A. & Sturm, A. C. Heterozygous Familial Hypercholesterolemia. Circulation 133, e587\u2013589, https:\/\/doi.org\/10.1161\/circulationaha.115.020701 (2016).","journal-title":"Circulation"},{"key":"27248_CR2","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","volume":"5","author":"PN Hopkins","year":"2011","unstructured":"Hopkins, P. N., Toth, P. P., Ballantyne, C. M. & Rader, D. J. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5, S9\u201317, https:\/\/doi.org\/10.1016\/j.jacl.2011.03.452 (2011).","journal-title":"J Clin Lipidol"},{"key":"27248_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","volume":"168","author":"D Marks","year":"2003","unstructured":"Marks, D., Thorogood, M., Neil, H. A. & Humphries, S. E. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168, 1\u201314 (2003).","journal-title":"Atherosclerosis"},{"key":"27248_CR4","doi-asserted-by":"publisher","first-page":"e000028","DOI":"10.1161\/JAHA.112.000028","volume":"2","author":"F Raal","year":"2013","unstructured":"Raal, F., Panz, V., Immelman, A. & Pilcher, G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc 2, e000028, https:\/\/doi.org\/10.1161\/jaha.112.000028 (2013).","journal-title":"J Am Heart Assoc"},{"key":"27248_CR5","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard, B. G. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J 34, 3478\u20133490a, https:\/\/doi.org\/10.1093\/eurheartj\/eht273 (2013).","journal-title":"Heart J"},{"key":"27248_CR6","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1210\/jc.2012-1563","volume":"97","author":"M Benn","year":"2012","unstructured":"Benn, M., Watts, G. F., Tybjaerg-Hansen, A. & Nordestgaard, B. G. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 97, 3956\u20133964, https:\/\/doi.org\/10.1210\/jc.2012-1563 (2012).","journal-title":"J Clin Endocrinol Metab"},{"key":"27248_CR7","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jacl.2016.06.002","volume":"10","author":"MB Mortensen","year":"2016","unstructured":"Mortensen, M. B., Kulenovic, I., Klausen, I. C. & Falk, E. Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation. J Clin Lipidol 10, 1145\u20131152.e1141, https:\/\/doi.org\/10.1016\/j.jacl.2016.06.002 (2016).","journal-title":"J Clin Lipidol"},{"key":"27248_CR8","first-page":"1876","volume":"97","author":"SM Grundy","year":"1998","unstructured":"Grundy, S. M. et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 97, 1876\u20131887 (1998).","journal-title":"American Heart Association. Circulation"},{"key":"27248_CR9","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/jama.1993.03500110084041","volume":"269","author":"SB Hulley","year":"1993","unstructured":"Hulley, S. B. et al. Should we be measuring blood cholesterol levels in young adults? Jama 269, 1416\u20131419 (1993).","journal-title":"Jama"},{"key":"27248_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1161\/01.CIR.97.8.729","volume":"97","author":"ME Wittekoek","year":"1998","unstructured":"Wittekoek, M. E. et al. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 97, 729\u2013735 (1998).","journal-title":"Circulation"},{"key":"27248_CR11","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jacl.2016.08.013","volume":"10","author":"S Li","year":"2016","unstructured":"Li, S. et al. Identification of familial hypercholesterolemia in patients with myocardial infarction: A Chinese cohort study. J Clin Lipidol 10, 1344\u20131352, https:\/\/doi.org\/10.1016\/j.jacl.2016.08.013 (2016).","journal-title":"J Clin Lipidol"},{"key":"27248_CR12","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0735-1097(00)00556-8","volume":"35","author":"KO Akosah","year":"2000","unstructured":"Akosah, K. O., Gower, E., Groon, L., Rooney, B. L. & Schaper, A. Mild hypercholesterolemia and premature heart disease: do the national criteria underestimate disease risk? J Am Coll Cardiol 35, 1178\u20131184 (2000).","journal-title":"J Am Coll Cardiol"},{"key":"27248_CR13","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1378\/chest.120.6.1953","volume":"120","author":"KO Akosah","year":"2001","unstructured":"Akosah, K. O., Cerniglia, R. M., Havlik, P. & Schaper, A. Myocardial infarction in young adults with low-density lipoprotein cholesterol levels or\u2009=\u2009100 mg\/dL: clinical profile and 1-year outcomes. Chest 120, 1953\u20131958 (2001).","journal-title":"Chest"},{"key":"27248_CR14","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","volume":"63","author":"AD Sniderman","year":"2014","unstructured":"Sniderman, A. D., Tsimikas, S. & Fazio, S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol 63, 1935\u20131947, https:\/\/doi.org\/10.1016\/j.jacc.2014.01.060 (2014).","journal-title":"J Am Coll Cardiol"},{"key":"27248_CR15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(13)60187-7","volume":"381","author":"EA Stein","year":"2013","unstructured":"Stein, E. A. & Raal, F. J. Polygenic familial hypercholesterolaemia: does it matter? Lancet 381, 1255\u20131257, https:\/\/doi.org\/10.1016\/s0140-6736(13)60187-7 (2013).","journal-title":"Lancet"},{"key":"27248_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ahj.2016.08.001","volume":"181","author":"SA Rerup","year":"2016","unstructured":"Rerup, S. A. et al. The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction. Am Heart J 181, 35\u201342, https:\/\/doi.org\/10.1016\/j.ahj.2016.08.001 (2016).","journal-title":"Am Heart J"},{"key":"27248_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2015.03.003","volume":"240","author":"K Haralambos","year":"2015","unstructured":"Haralambos, K. et al. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis 240, 190\u2013196, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.03.003 (2015).","journal-title":"Atherosclerosis"},{"key":"27248_CR18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacl.2016.06.007","volume":"10","author":"S Beliard","year":"2016","unstructured":"Beliard, S. et al. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients. J Clin Lipidol 10, 1129\u20131136.e1123, https:\/\/doi.org\/10.1016\/j.jacl.2016.06.007 (2016).","journal-title":"J Clin Lipidol"},{"key":"27248_CR19","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.lpm.2013.01.053","volume":"42","author":"M Farnier","year":"2013","unstructured":"Farnier, M., Bruckert, E., Boileau, C. & Krempf, M. [Diagnostic and treatment of familial hypercholesterolemia (FH) in adult: guidelines from the New French Society of Atherosclerosis (NSFA)]. Presse Med 42, 930\u2013950, https:\/\/doi.org\/10.1016\/j.lpm.2013.01.053 (2013).","journal-title":"Presse Med"},{"key":"27248_CR20","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.jacl.2011.03.451","volume":"5","author":"JG Robinson","year":"2011","unstructured":"Robinson, J. G. & Goldberg, A. C. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5, S18\u201329, https:\/\/doi.org\/10.1016\/j.jacl.2011.03.451 (2011).","journal-title":"J Clin Lipidol"},{"key":"27248_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00392-013-0555-4","volume":"102","author":"C Sinning","year":"2013","unstructured":"Sinning, C. et al. Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clin Res Cardiol 102, 495\u2013503, https:\/\/doi.org\/10.1007\/s00392-013-0555-4 (2013).","journal-title":"Clin Res Cardiol"},{"key":"27248_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0002-9149(83)80105-2","volume":"51","author":"GG Gensini","year":"1983","unstructured":"Gensini, G. G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51, 606 (1983).","journal-title":"Am J Cardiol"},{"key":"27248_CR23","doi-asserted-by":"publisher","first-page":"e2426","DOI":"10.1097\/MD.0000000000002426","volume":"94","author":"JJ Li","year":"2015","unstructured":"Li, J. J. et al. Proprotein Convertase Subtilisin\/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study. Medicine (Baltimore) 94, e2426, https:\/\/doi.org\/10.1097\/md.0000000000002426 (2015).","journal-title":"Medicine (Baltimore)"},{"key":"27248_CR24","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","volume":"63","author":"R Alonso","year":"2014","unstructured":"Alonso, R. et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 63, 1982\u20131989, https:\/\/doi.org\/10.1016\/j.jacc.2014.01.063 (2014).","journal-title":"J Am Coll Cardiol"},{"key":"27248_CR25","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.jacc.2013.12.049","volume":"63","author":"RD Santos","year":"2014","unstructured":"Santos, R. D. Lipoprotein(a) and cardiovascular disease in heterozygous familial hypercholesterolemia: should we also blame the LDL receptor? J Am Coll Cardiol 63, 1990\u20131991, https:\/\/doi.org\/10.1016\/j.jacc.2013.12.049 (2014).","journal-title":"J Am Coll Cardiol"},{"key":"27248_CR26","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1161\/CIRCULATIONAHA.111.065904","volume":"125","author":"W Yang","year":"2012","unstructured":"Yang, W. et al. Serum lipids and lipoproteins in Chinese men and women. Circulation 125, 2212\u20132221, https:\/\/doi.org\/10.1161\/circulationaha.111.065904 (2012).","journal-title":"Circulation"},{"key":"27248_CR27","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00134-010-1832-6","volume":"36","author":"J Mercado-Martinez","year":"2010","unstructured":"Mercado-Martinez, J. et al. APACHE-II score and Killip class for patients with acute myocardial infarction. Intensive Care Med 36, 1579\u20131586, https:\/\/doi.org\/10.1007\/s00134-010-1832-6 (2010).","journal-title":"Intensive Care Med"},{"key":"27248_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2016.03.023","volume":"249","author":"LS Rallidis","year":"2016","unstructured":"Rallidis, L. S. et al. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins. Atherosclerosis 249, 17\u201321, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.03.023 (2016).","journal-title":"Atherosclerosis"},{"key":"27248_CR29","doi-asserted-by":"publisher","first-page":"e0186815","DOI":"10.1371\/journal.pone.0186815","volume":"12","author":"R Auckle","year":"2017","unstructured":"Auckle, R. et al. Familial hypercholesterolemia in Chinese patients with premature ST-segment-elevation myocardial infarction: Prevalence, lipid management and 1-year follow-up. PLoS One 12, e0186815, https:\/\/doi.org\/10.1371\/journal.pone.0186815 (2017).","journal-title":"PLoS One"},{"key":"27248_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","volume":"241","author":"G De Backer","year":"2015","unstructured":"De Backer, G. et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis 241, 169\u2013175, https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.04.809 (2015).","journal-title":"Atherosclerosis"},{"key":"27248_CR31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/01.ATV.18.2.309","volume":"18","author":"SN Pimstone","year":"1998","unstructured":"Pimstone, S. N. et al. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler Thromb Vasc Biol 18, 309\u2013315, https:\/\/doi.org\/10.1161\/01.ATV.18.2.309 (1998).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"27248_CR32","doi-asserted-by":"crossref","unstructured":"Cannon, C. P. et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine 372(25), 2387\u20132397 (2015).","DOI":"10.1056\/NEJMoa1410489"},{"key":"27248_CR33","doi-asserted-by":"publisher","unstructured":"Besseling, J., Hovingh, G. K., Huijgen, R., Kastelein, J. J. & Hutten, B. A. Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality. J Am Coll Cardiol 68, 252\u2013260, https:\/\/doi.org\/10.1016\/j.jacc.2016.04.054 (2016).","DOI":"10.1016\/j.jacc.2016.04.054"},{"key":"27248_CR34","doi-asserted-by":"crossref","unstructured":"Perez de Isla, L. et al. Attainment of LDL-Cholesterol Treatment\u00c2 Goals in Patients With Familial\u00c2 Hypercholesterolemia. Journal of the American College of Cardiology 67(11), 1278\u20131285 (2016).","DOI":"10.1016\/j.jacc.2016.01.008"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27248-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27248-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27248-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:13:09Z","timestamp":1671603189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27248-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["27248"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-27248-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,11]]},"assertion":[{"value":"20 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8861"}}